GlobeNewswire Inc.··NaXORTX Bolsters Kidney Disease Pipeline With $3M Vectus Acquisition
XORTX acquires Vectus kidney fibrosis asset VB4-P5 for $3M, expanding pipeline in high-potential CKD therapeutics market.
XRTXacquisitionkidney disease
X
$XRTX
5 articles found3 positive
1 negative
1 neutral
GlobeNewswire Inc.··NaGlobeNewswire Inc.··Xortx Therapeutics Inc.XORTX Therapeutics Completes 1-for-5 Share Consolidation Effective April 6
XORTX Therapeutics completes 1-for-5 share consolidation effective April 6, 2026, receiving TSX Venture Exchange and Nasdaq approvals. Clinical-stage pharma firm developing gout and kidney disease therapies.
XRTXclinical trialskidney disease
GlobeNewswire Inc.··NaXORTX Shareholders Greenlight Board Overhaul and Share Consolidation
XORTX Therapeutics shareholders approved all proposals at March 24 meeting with 35% representation, including new leadership and share consolidation.
XRTXclinical trialskidney disease
GlobeNewswire Inc.··NaXORTX Shareholders Back 5-to-1 Consolidation to Avert NASDAQ Delisting
XORTX shareholders approved a 5-to-1 share consolidation to maintain NASDAQ compliance, reducing shares from 6.96M to 1.39M ahead of April 2026 deadline.
XRTXkidney diseaseshare consolidation
GlobeNewswire Inc.··Xortx Therapeutics Inc.XORTX Wins ISS Backing for Share Consolidation Plan Ahead of March Vote
XORTX Therapeutics secures ISS endorsement for share consolidation, with proxy advisor backing March 2026 shareholder vote. ISS cited no direct shareholder value impact while noting improved financing prospects.
XRTXkidney diseaseshare consolidation